The biotech company Archivel Farma has officially begun the clinical trial of its therapeutic vaccine RUTI® in India. The double-blind, randomized, placebo-controlled phase IIb clinical trial will investigate the efficacy of RUTI® as adjuvant of Tuberculosis (TB) chemotherapy and will recruit 90 patients with TB and 50 patients with multi-drug resistant TB (MDR-TB).

The clinical trials will be conducted by the CRO Clinical  Research Network India in two centers in the country, in New Delhi and Agartala. The first patient in the trial has been recruited on 30 September. "For Archivel it represents a great milestone since it brings the opportunity to get closer to new clinical findings that are expected to contribute to the future deployment of the RUTI® vaccine worldwide to improve the life of those affected by the disease." said Olga Rué, Chief Executive Officer of Archivel Farma, a CataloniaBio &  HealthTech member.

The clinical trial is jointly funded in the STriTuVaD Consortium project by the EC-Horizon 2020 program and the Department of Biotechnology of the Indian Government.

Archivel Farma, a biotechnology firm founded in 2005 in Barcelona, works on the development of the RUTI® immunotherapeutic agent, with the goal of developing the RUTI® vaccine for different indications up to advanced clinical phases and license it to companies in the pharmaceutical sector that can bring it to market.

You may also be interested in:

• Archivel Farma creates a subsidiary with the RUTI® vaccine for Covid-19
  
• Archivel's Ruti® vaccine begins clinical trial to increase the immunity of healthcare professionals exposed to Covid-19